CTNMHealthcare · BiotechnologyThe 8 Wall Street analysts covering Contineum Therapeutics, Inc. hold a median 12-month price target of $22 — +135.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Contineum Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (68): Sales and profits are climbing, and climbing faster than before.
Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CTNM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +135.8% from it.
Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Oct 2026 | Jones Trading | Maintains | Buy | $24 → $30 |
| 14 Oct 2026 | Baird | Downgrade | Neutral | $19 → $14 |
| 28 Sept 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 28 Sept 2026 | Morgan Stanley | Maintains | Equal-Weight | $18 → $17 |
| 15 Sept 2026 | Baird | Maintains | Outperform | $20 → $19 |
| 15 Sept 2026 | Baird | Maintains | Outperform | — |
| 15 Sept 2026 | Jones Trading | Maintains | Buy | — |
| 15 Sept 2026 | Jones Trading | Maintains | Buy | $26 → $24 |
| 31 July 2026 | RBC Capital | Maintains | Outperform | $22 → $23 |
| 31 July 2026 | RBC Capital | Maintains | Outperform | — |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $14 → $16 |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 6 Mar 2026 | Baird | Maintains | Outperform | — |
| 8 Jan 2026 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 24 Nov 2025 | Baird | Maintains | Outperform | — |
| 21 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 25 Sept 2025 | Leerink Partners | Initiates | Outperform | — |
| 18 Aug 2025 | Morgan Stanley | Maintains | Overweight | — |
| 19 May 2025 | Morgan Stanley | Maintains | Overweight | — |
| 15 May 2025 | RBC Capital | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CTNM appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Contineum Therapeutics, Inc. returned −14.4% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 29% of US stocks
Cheaper than 55% of US stocks
Cheaper than 72% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 28% of US stocks
Higher than 20% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Contineum Therapeutics, Inc. has a market value of $344.2M and an enterprise value of $114.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$57.6M.
Diluted earnings per share, trailing twelve months: $−1.73.
Free cash flow in the twelve months to 30 June 2026: −$53.5M.
Trailing P/E: 26.0×; forward P/E: −4.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Contineum Therapeutics, Inc. employs 51 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Contineum Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Contineum Therapeutics announced that management is scheduled to present at the Stifel 2026 Healthcare Conference on Thursday, November 12, at 8:40 a.m. ET. An audio webcast of the fireside chat will be available through the Investors section of the company’s website.
Why it matters — CTNM watchers can follow management’s conference remarks through the announced webcast.
Contineum Therapeutics (CTNM) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects.
Why it matters — CTNM watchers may note the rating change as an indicator of increased optimism about the company’s earnings outlook.
Contineum Therapeutics shares plunged Monday after mixed Phase 3 trial results for Bristol Myers Squibb’s competing lung disease drug, admilparant.
Why it matters — The trial results involving a competing lung disease drug were cited alongside the decline in CTNM shares.
Contineum Therapeutics shares fell on Tuesday after disappointing Phase 2 results from a key study of its depression drug, a program developed in partnership with Johnson & Johnson. The trial failure weighed on investor sentiment for the company.
Why it matters — A CTNM watcher would care because the failed Phase 2 depression trial represents a setback for one of the company's key partnered pipeline programs.
Contineum Therapeutics announced that its MOONLIGHT-1 Phase 2 trial evaluating JNJ-5120/PIPE-307 for major depressive disorder did not achieve its primary efficacy endpoint of improvement in MADRS total score at Day 5 versus placebo.
Why it matters — A missed primary endpoint for a key clinical candidate in Phase 2 represents a significant setback for the company's pipeline.
The 8 Wall Street analysts covering Contineum Therapeutics, Inc. have a median 12-month price target of $22, with estimates ranging from $14 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Contineum Therapeutics, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Contineum Therapeutics, Inc. 32 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Contineum Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (68 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +135.8% from the last close, and Ticker Nerd's factor model ranks Contineum Therapeutics, Inc. 32 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Contineum Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $30 over the next 12 months.
Contineum Therapeutics, Inc. returned -14.4% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Contineum Therapeutics Inc. Class A Common Stock represents ownership in Contineum Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for neuroscience, inflammation, and immunology indications.
The most recent item we track (Business Wire, 29 Oct 2026): "Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference". Contineum Therapeutics announced that management is scheduled to present at the Stifel 2026 Healthcare Conference on Thursday, November 12, at 8:40 a.m. ET. An audio webcast of the fireside chat will be available through the Investors section of the company’s website.
Contineum Therapeutics Inc. Class A Common Stock represents ownership in Contineum Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for neuroscience, inflammation, and immunology indications. The company’s current pipeline is centered on internally developed drug candidates designed to address conditions with significant unmet medical need, including programs targeting pulmonary fibrosis, chronic pain, depression, and multiple sclerosis. Contineum Therapeutics works at the intersection of drug discovery and clinical development, advancing therapies intended to modulate specific biological pathways relevant to these disease areas. Its business is concentrated on research, development, and advancement of candidate medicines rather than commercial product sales, making the stock closely tied to progress in its clinical and regulatory pipeline. Based in San Diego, California, Contineum Therapeutics plays a specialized role in the biotechnology market as a developer of novel therapies for complex inflammatory and neurological disorders.
CEO Mr. Carmine N. Stengone MBA, MS · 51 employees · United States · https://www.contineum-tx.com
